{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:00:23Z","timestamp":1791608423851,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":6281,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1111\/j.1538-7836.2005.01435.x","type":"journal-article","created":{"date-parts":[[2005,9,29]],"date-time":"2005-09-29T11:18:54Z","timestamp":1127992734000},"page":"2219-2227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Pharmacokinetic studies on Wilfactin\u00ae, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation\/removal methods"],"prefix":"10.1016","volume":"3","author":[{"given":"J.","family":"GOUDEMAND","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"SCHARRER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"BERNTORP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"LEE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"BOREL-DERLON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"STIELTJES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"CARON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"SCHERRMANN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"BRIDEY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"TELLIER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"FEDERICI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"MANNUCCI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0010","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood.V97.7.1915","article-title":"How I treat patients with von Willebrand disease","volume":"97","author":"Mannucci","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0015","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0037-1613992","article-title":"Impact, diagnosis and treatment of von Willebrand disease","volume":"84","author":"Sadler","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0037-1963(03)80740-0","article-title":"The spectrum of safety: a review of the safety of current hemophilia products","volume":"3","author":"Luban","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0025","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1055\/s-0038-1649942","article-title":"A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with VWD unresponsive to DDAVP: results of an international study","volume":"74","author":"Foster","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2516.1998.0040s3001.x","article-title":"Summary of a workshop on potency and dosage of von Willebrand factor concentrates","volume":"4","author":"Chang","year":"1998","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2516.2003.00711.x","article-title":"Guidelines on the selection and use of therapeutic products to treat haemophilia and other bleeding disorders","volume":"9","year":"2003","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0040","first-page":"1","article-title":"In vitro evaluation of a very-high-purity, solvent\/detergent-treatment, von Willebrand factor concentrate","volume":"61","author":"Mazurier","year":"1991","journal-title":"Vox Sang"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0045","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-2141.1992.tb08903.x","article-title":"Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity","volume":"80","author":"Goudemand","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0050","unstructured":"The European Agency for the Evaluation of Medicinal Products. Note for Guidance on Plasma-derived Medicinal Products. London, UK: Human Medicines Evaluation Unit, 25 January 2001, CPMP\/BWP\/269\/95 rev.3."},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0055","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.0042-9007.2004.00398.x","article-title":"In vitro study of a triple-secured von Willebrand factor concentrate","volume":"86","author":"Mazurier","year":"2004","journal-title":"Vox Sang"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0060","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/s-0037-1613225","article-title":"Venous thromboembolism in von Willebrand's disease","volume":"88","author":"Mannucci","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-0037-1613227","article-title":"Venous thrombosis following the use of intermediate purity FVIII concentrates to treat patients with von Willebrand's disease","volume":"88","author":"Makris","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0070","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2003-06-2072","article-title":"Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study","volume":"103","author":"Federici","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0075","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0038-1656323","volume":"68","author":"Mannucci","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0080","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1365-2141.1995.tb08411.x","article-title":"Interpretation of measured red cell mass and plasma volume in adults: Expert panel on Radionuclides of the International Council for Standardization in Haematology","volume":"89","author":"Pearson","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0085","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1046\/j.1365-2141.1996.d01-1860.x","article-title":"Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis","volume":"94","author":"Menache","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0090","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","article-title":"A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability","volume":"15","author":"Schuirmann","year":"1987","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0095","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00001721-199304060-00018","article-title":"Biological effects of S\/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease","volume":"4","author":"Meriane","year":"1993","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2516.1998.0040s3044.x","article-title":"Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2","volume":"4","author":"Menache","year":"1998","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1365-2516.1998.0040s3033.x","article-title":"Pharmacokinetics, efficacy and safety of Humate-P\u00ae in von Willebrand disease","volume":"4","author":"Dobrkovska","year":"1998","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0110","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V99.2.450","article-title":"Treatment of von Willebrand disease with a high-purity factor VIII\/von Willebrand factor concentrate: a prospective, multicenter study","volume":"99","author":"Mannucci","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0037-1613747","article-title":"High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism","volume":"83","author":"Kraaijenhagen","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0120","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.ATV.21.5.731","article-title":"Elevated factor VIII levels and the risk of thrombosis","volume":"21","author":"Kamphuisen","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0125","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1365-2141.2001.03146.x","article-title":"Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism","volume":"115","author":"O'Donnell","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0130","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1365-2141.2003.04795.x","article-title":"High plasma levels of factor VIII and risk of recurrence of venous thromboembolism","volume":"124","author":"Legnani","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2516.1998.0040s3048.x","article-title":"Clinical management of patients with von Willebrand disease with a VHP vWF concentrate: the French experience","volume":"4","author":"Goudemand","year":"1998","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0140","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-2516.2002.00688.x","article-title":"Clinical efficacy of highly purified, doubly virus-inactivated factor VIII\/von Willebrand factor concentrate (Fandhi\u00ae) in the treatment of von Willebrand disease: a retrospective clinical study","volume":"8","author":"Federici","year":"2002","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0145","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-2002-27822","article-title":"Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII\/von Willebrand factor concentrate (Immunate\u00ae)","volume":"28","author":"Auerswald","year":"2002","journal-title":"Semin Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0150","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1046\/j.1365-2516.2002.00673.x","article-title":"Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience","volume":"8","author":"Lubetsky","year":"2002","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2005.01435.x_bb0155","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1055\/s-0037-1612977","article-title":"Efficacy and safety of the factor VIII\/von Willebrand factor concentrate, Haemate-P\/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease","volume":"87","author":"Lillicrap","year":"2002","journal-title":"Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2005.01435.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622165700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622165700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2005.01435.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:31:42Z","timestamp":1761532302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622165700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S1538783622165700"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01435.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic studies on Wilfactin\u00ae, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation\/removal methods","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01435.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}